2013
DOI: 10.1167/iovs.13-12771
|View full text |Cite
|
Sign up to set email alerts
|

Effect of Intravitreal Injection of Bevacizumab on Optic Nerve Head Leakage and Retinal Ganglion Cell Survival in a Mouse Model of Optic Nerve Crush

Abstract: Bevacizumab treatment following ONC induction exerts a protective effect, manifested by reduced optic nerve head edema. The underlying mechanism probably involves a lesser interruption of axonal transport. Reduced expression of antioxidative and ischemic genes may contribute to RGC preservation.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
9
0
1

Year Published

2014
2014
2020
2020

Publication Types

Select...
6
1
1

Relationship

3
5

Authors

Journals

citations
Cited by 13 publications
(10 citation statements)
references
References 58 publications
0
9
0
1
Order By: Relevance
“…18 However, anti-VEGF agents were reported to contribute to RGC preservation in a mouse model of ON crush. 19 In an animal laser-induced choroidal neovascularization, no significant reduction was found in retinal function, the retinal level of mRNA for ganglion cell-specific genes, and RGC axon count after blockage of VEGF for 7 months in transgenic mice. 20 To the best of our knowledge, anti-VEGF agents have never been evaluated in a rat model of anterior ischemic optic neuropathy (rAION).…”
mentioning
confidence: 94%
“…18 However, anti-VEGF agents were reported to contribute to RGC preservation in a mouse model of ON crush. 19 In an animal laser-induced choroidal neovascularization, no significant reduction was found in retinal function, the retinal level of mRNA for ganglion cell-specific genes, and RGC axon count after blockage of VEGF for 7 months in transgenic mice. 20 To the best of our knowledge, anti-VEGF agents have never been evaluated in a rat model of anterior ischemic optic neuropathy (rAION).…”
mentioning
confidence: 94%
“…It should be noted that these retinal vascular disorders are always accompanied by neuronal damage [11]. Although anti-VEGF treatments have been extensively administered for neovascular eye diseases [12], they are likely to aggravate this neuronal injury and thus deteriorate visual function [13]. To solve this dilemma, a treatment that can protect neurons and simultaneously inhibit angiogenesis is urgently needed.…”
Section: Discussionmentioning
confidence: 99%
“…Clinical findings on the benefit of bevacizumab were supported in a murine model of ONC, showing that the drug preserved the integrity of the microvasculature (56). This apparently prevented post-ONC ischemia from spreading from the site of injury to the immediate retrobulbar portion of the nerve.…”
Section: Animal Models Of Na-aion: the Future Targets Of Medical Treamentioning
confidence: 98%